AAVantgarde Bio S.r.l.

Based in Lombardy, Italy, and founded in 2021 by Alberto Auricchio, AAVantgarde Bio S. r. l. operates as a biotechnology company that specializes in the development of AAV-based gene delivery platforms.

In November 2025, AAVantgarde Bio S. r. l. raised USD 141 million in Series B funding, co-led by new investor Schroders Capital and returning investors Atlas Venture and Forbion, with participation from other new investors Amgen Ventures, Athos Capital, CDP Venture Capital, Columbia University Endowment, Neva, Sixty Degree Capital, XGen Venture, and Willett Advisors.

Returning investors Longwood Fund and Sofinnova Partners also participated in the round. AAVantgarde Bio S. r. l.

has developed two technologies that enable the delivery of large genes to tissues and cells in vivo. The two technologies are a dual hybrid platform that leverages DNA recombination to deliver large genes to targeted tissues and cells; the AAV Intein Platform utilizes protein trans-splicing to facilitate the delivery of large genes to specific tissues and cells. Its product pipeline includes Usher Syndrome Type 1 B associated retinitis pigmentosa, and Stargardt disease. The company intends to use the November 2025 funding to complete clinical proof-of-concept studies for Stargardt disease and Usher 1B syndrome and advance its gene therapy programs.